Sign In
Buy BIXT
$0.0300
-0.0001 (-0.332%)
At Close: Jun 03, 2026
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
08:03am, Friday, 29'th May 2026
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company
Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest
02:58am, Wednesday, 25'th Mar 2026
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a dec
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
09:05am, Friday, 20'th Mar 2026
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology c
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
03:40pm, Wednesday, 04'th Mar 2026
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, In
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomize
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
06:00am, Wednesday, 11'th Feb 2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, do
Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update
04:18am, Wednesday, 11'th Feb 2026
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 5,695 shares, an increase of 1,798.3% from the
Bioxytran Conference: CEO touts broad-spectrum antiviral strategy, cites strong COVID Phase II results
01:12am, Saturday, 07'th Feb 2026
Bioxytran (OTCMKTS:BIXT) CEO David Platt outlined the company's focus on developing drugs based on polysaccharides-complex carbohydrates-across three areas: antiviral treatment, early-stage stroke car
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
07:00am, Monday, 02'nd Feb 2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning
Bioxytran (OTCMKTS:BIXT) vs. Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Survey
01:58am, Sunday, 21'st Dec 2025
Bioxytran (OTCMKTS:BIXT - Get Free Report) and Structure Therapeutics (NASDAQ: GPCR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies b
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
08:10am, Tuesday, 09'th Dec 2025
MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
01:50pm, Thursday, 13'th Nov 2025
BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, a
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
09:30am, Wednesday, 29'th Oct 2025
BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, i
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
12:13pm, Friday, 15'th Aug 2025
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, i
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
09:00am, Thursday, 07'th Aug 2025
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT
